Every year in the U cialis for women dosage.

Every year in the U.S. More people die from staph infections cialis for women dosage . HIV Infections of the skin alone for more than 10,000 patient visits to the U.S. Staphylococcus is the most frequently identified bacteria infections of the skin and is a potential pathogen in almost any type of infection is the most common bacterial pathogens makes Staphylococcus in a large and diverse patient population.

The objectives of the study are effectiveness, -1252. Of 200 mg oral confirm AFN-1252 twice daily for 5-14 days in patients with severe, suspected staphylococcal skin infections in outpatient or emergency room settings recruited doses. The study evaluates both traditional endpoints at the end of treatment and early endpoints currently recommended by the FDA. We are pleased with the ease and speed of patient recruitment in our study are very pleased, said Dr. Barry Hafkin, Chief Medical Officer, said at Affinium. Hafkin noted that the investigator the possibility of adding a second antibiotic to cover other potential pathogens or admit the patient to hospital, the majority of patients were treated with AFN-1252 as monotherapy in the outpatient area. We believe that this study shows investigator confidence in identification of staphylococcal infection of the skin and with AFN-1252. In the treatment of severe staphylococcal infections of the skin The exquisite potency of AFN-1252 against all strains of Staphylococcus including MRSA and VISA through a unique new mechanism of action, and the excellent safety profile in several oral Phase 1 studies showed were attributes that our investigators, enthuses Hafkin determined. – Affinium Pharmaceuticals announced today that full recruitment in its multicenter phase 2 clinical trial to evaluate oral AFN-1252 and in acute bacterial skin skin structure infections has been reached. This Phase 2 trial is the first human efficacy study a new class of a new class of specifically inhibit specifically inhibit staphylococcal fatty acid biosynthesis via a novel target, the fatty acid synthase II performed system. Results are expected late 2012 a significant proof-of-concept milestone for this unique, Staphylococcus specific antibiotic, AFN-1252 pose.

Occasion of the report start Host MEP and Vice Chairman to the Disability Intergroup, stated MEP Cecilia Wikstr m This pain helping initiative of to increase the awareness of personal, social and economic impact for chronic pain in Europe and draws the need for a efficient healthcare to improve patient power supply? .

– The initiative was proposed by by pain Steering Committee, is a group led by top European experts in in the areas chronic pain, politics and economy that was the first meeting in January 2010. 2010 theIn July of 2010, the pains proposed Steering of pain proposal from the Executive Committee meeting 50 experts from 15 countries Europe, the debate about that which measures should be taken to enhance to improve chronic pains.